Nurexone Biologic Inc (NRX.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 56 | 53 | 47 | 42 | 43 |
| Accounts receivable | 25 | -72 | -37 | 57 | 161 |
| Other Working Capital | 32 | -193 | -195 | 424 | 336 |
| Other Operating Activity | -1,349 | -962 | -1,099 | -1,590 | -1,526 |
| Operating Cash Flow | $-1,236 | $-1,174 | $-1,284 | $-1,067 | $-986 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -2 | -9 | -12 | -2 | -32 |
| Investing Cash Flow | $-2 | $-9 | $-12 | $-2 | $-32 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -8 | -10 | -8 | -1 | -3 |
| Common Stock Issued | 633 | 6 | 998 | 1,591 | 310 |
| Other Financing Activity | 0 | 2,276 | 72 | 0 | 603 |
| Financing Cash Flow | $625 | $2,272 | $1,062 | $1,590 | $910 |
| Exchange Rate Effect | -15 | 66 | -11 | 119 | -4 |
| Beginning Cash Position | 2,138 | 983 | 1,228 | 588 | 700 |
| End Cash Position | 1,510 | 2,138 | 983 | 1,228 | 588 |
| Net Cash Flow | $-613 | $1,089 | $-234 | $521 | $-108 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,236 | -1,174 | -1,284 | -1,067 | -986 |
| Capital Expenditure | -2 | -9 | -12 | -2 | -32 |
| Free Cash Flow | -1,238 | -1,183 | -1,296 | -1,069 | -1,018 |